Back to top
more

Bristol Myers Squibb (BMY)

(Delayed Data from NYSE)

$53.76 USD

53.76
22,196,871

+0.86 (1.63%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $53.98 +0.22 (0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

AbbVie's Elagolix Meets Primary Endpoint in Phase II Study

AbbVie Inc. (ABBV) along with Neurocrine Biosciences, Inc. (NBIX) announced positive results from a phase IIb study evaluating its pipeline candidate elagolix for reducing heavy menstrual bleeding in premenopausal women with uterine fibroids.

    Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549

    We issued an updated report on Infinity Pharmaceuticals, Inc. (INFI) on Apr 7.

      Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA

      Bristol-Myers Squibb Company (BMY) recently announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) for the label expansion of immune-oncology drug Opdivo.

        5 Reasons to Invest in Eli Lilly (LLY) Stock Right Now

        Lily carries a Zacks Rank #2 (Buy).

          Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo

          Bristol-Myers Squibb Company (BMY) recently announced encouraging data from various trials on Opdivo.

            Bristol-Myers (BMY), Incyte to Advance Clinical Program

            Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.

              Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage

              Shares of Athersys, Inc. (ATHX) surged significantly in the post market trading on Mar 28 after research firm William Blair initiated a coverage on the stock with an outperform rating.

                Bristol-Myers (BMY) Opdivo Gets Positive CHMP Opinion

                Bristol-Myers Squibb Company (BMY) announced that the CHMP has recommended the approval of immunotherapy Opdivo as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults.

                  Arpita Dutt headshot

                  Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved

                  This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.

                    Infinity Pharma Focuses on Cancer Drug: Competition Looms

                    We issued an updated research report on Infinity Pharmaceuticals, Inc. (INFI) on Mar 20, 2017.

                      Bristol-Myers Squibb and CytomX Therapeutics Extend Deal

                      Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. (CTMX), announced an expansion of their 2014 strategic collaboration to discover novel therapies.

                        6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017

                        Glaxo carries a Zacks Rank #2 (Buy).

                          Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat

                          Celldex Therapeutics, Inc. (CLDX) posted fourth-quarter 2016 loss of 30 cents per share, narrower than both the Zacks Consensus Estimate of a loss of 34 cents and the year-ago loss of 33 cents.

                            Sweta Killa headshot

                            Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs

                            President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.

                              Repros (RPRX) Q4 Earnings: What's in Store for the Stock?

                              Repros Therapeutics Inc. (RPRX) is expected to report fourth-quarter 2016 results this month.

                                Catalyst Pharma (CPRX): What???s in Store in Q4 Earnings?

                                Catalyst Pharmaceuticals, Inc. (CPRX) is expected to report fourth-quarter 2016 results this month.

                                  AVEO Pharmaceuticals (AVEO) Q4 Earnings: What's in Store?

                                  AVEO Pharmaceuticals, Inc. (AVEO) is expected to report fourth-quarter 2016 results this month.

                                    What's in Store for Merck KGaA (MKGAF) in Q4 Earnings?

                                    Merck KGaA (MKGAF) is scheduled to report fourth-quarter 2016 earnings results on Mar 9.

                                      Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?

                                      Celldex Therapeutics, Inc. (CLDX) is expected to report fourth-quarter 2016 results on Mar 4 after market close.

                                        Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4

                                        Nektar Therapeutics (NKTR) reported loss of 28 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of loss of 26 cents.

                                          Aduro (ADRO) Loss Wider than Expected, Sales Miss in Q4

                                          Aduro BioTech, Inc. (ADRO) reported fourth-quarter 2016 loss of 44 cents per share, wider than the Zacks Consensus Estimate of a loss of 38 cents.

                                            Aerie Pharmaceuticals (AERI) Q4 Earnings: What to Expect?

                                            Aerie Pharmaceuticals, Inc. (AERI) is expected to report fourth-quarter 2016 results on Mar 7.

                                              Exelixis (EXEL) Reports Q4 Earnings, Revenues Beat Y/Y

                                              Exelixis, Inc.(EXEL) posted fourth-quarter 2016 earnings of 12 cents, compared with loss of 18 cents per share in the year ago quarter.

                                                Bristol-Myers (BMY) Up 20.5% Since Earnings Report: Can It Continue?

                                                Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                                  Arpita Dutt headshot

                                                  Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs

                                                  Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.